A UK government watchdog has said UK homes aren’t prepared for the possibility of food supply disruptions that could come from disasters like cyberattacks, power cuts, disease outbreaks or extreme weather.

The current government recommends that the public stock up on non-perishable food that doesn’t need cooking. But this vague guidance doesn’t really give us much to go on. So what should we buy to ensure we’re eating well in the event of a disaster?

Well, there are a couple of things to bear in mind.

First, eating only ready-to-eat or canned food long-term is never going to be ideal from a health perspective. This is because you’ll be missing out on fresh produce and all the vitamins it contains. And you could be getting a lot of salt in your diet, which tends to be high in canned foods.

Second, how long you’ll be “surviving” on these foods is key when building your stockpile. If it’s just a few days, it’s not really a big deal if the foods you’re eating are all that nutritionally balanced. But nutrition becomes key the longer you need to rely on your cupboard.

So for argument’s sake, let’s imagine you need to get by on your own supplies for a few weeks. Here’s how to do it in the healthiest way possible.

Protein

Let’s start with protein, which is important for maintaining muscle levels and keeping our metabolism functioning. On top of that, it’s one of the most filling types of nutrition. When food is limited for a few days or weeks, keeping hunger at bay is important.

Tinned meats, such as chicken, stewed steak or meatballs, can be useful and easy-to-eat sources of protein. Tinned fish, such as salmon, sardines, mackerel, herring and tuna, can also be good to stock up on. They’re also great sources of omega-3 fatty acids which are beneficial for the health of our brain, heart, skin and eyes.

You can boost nutrition if you get your sardines in tomato sauce. Tomatoes are rich in lycopene, a powerful antioxidant that is linked with lower levels of inflammation.

The only caveat with tinned fish is that pregnant women should eat no more than four cans of tuna per week. Women and girls of childbearing age should also limit consumption of oily fish (such as salmon) to no more than two portions a week. This is due to the potential mercury and pollutant content in these fish.

Tinned beans can also be a fantastic source of protein, as well as fibre and other vitamins and minerals. This is still true for baked beans, which also have the benefit of coming in a tasty tomato sauce.

Try buying lower salt versions of baked beans, or stock up on beans that have been canned in water (not salted water) to keep sodium levels down. That said, draining salted water from canned beans and fish before consuming goes a long way in reducing salt intake.

A few cartons of long life milk or skimmed milk powder can also be useful to have on hand. These can be added into meals for both calcium and protein.

Carbs

Carbs are a really valuable source of energy, which is why they should be a priority when building your stockpile. If you still have access to power and water, dried carbs such as brown rice, wholegrain pasta, porridge oats and wholemeal couscous are excellent staples to have. Microwave pouches of rice or grains can also be convenient.

Opting for wholegrain carbs gives you more fibre, vitamins and minerals. Fibre is hugely important for keeping you regular as well as for keeping you feeling fuller for longer, stabilising blood sugar after meals and feeding a healthy gut mircrobiome.

À lire aussi :
Frozen and tinned foods can be just as nutritious as fresh produce – here’s how

Having plenty of canned or jarred vegetables can also go a long way in ensuring you get important vitamins and minerals in your diet. Foods such as carrots, green beans, potatoes, tomatoes, sweetcorn, beans, peas and lentils contain nutrients such as iron, calcium, potassium and B vitamins, which are needed for a healthy metabolism.

Whole nuts and seeds are a useful, shelf-stable snack that can be a good source of vitamins, minerals, fibre and unsaturated fats as well.

Other key staples

Making sure the food in your emergency stockpile is tasty can’t be overstated. You don’t get any nutrition from the food you don’t eat, so stock up on jarred sauces or canned soups (just be careful of the salt content). You can mix these with your canned beans, veggies and proteins to make a relatively tasty, nutritionally-complete meal.

Some comfort foods in small amounts might also be worth having. Think canned rice pudding, custard, canned fruit in juice (also a great source of fibre and minerals) and maybe some jam, honey and biscuits. These could all help with the monotony of living off your stockpile for a few weeks.

One last thing worth considering is having a multivitamin and mineral supplement on hand. A diet of canned, ready-to-eat or dried food is probably going to be deficient in some nutrients, particularly vitamin C, which is very sensitive to processing.

Vitamin C is vital for immunity and maintaining healthy connective tissue, so a supplement can be useful. Taking vitamin C can also help you absorb iron – making it even more useful when diet quality isn’t the best.

Having a stockpile of unopened bottles of water is also a good idea. Around three to four litres per person per day is recommended – though you may also want to include extra for cooking and sanitation.

A food shortage is never going to be an ideal situation. But it is certainly possible to build a healthy stockpile for your home. Just don’t forget a can opener.

After a hearing earlier this year, the Upper Tribunal dismissed his challenge on Monday, finding that Mr Odey “has been willing either recklessly or deliberately to disregard regulations and structures put in place for the protection of consumers, when he considers it in his interests to do so”.

An inquiry into the sectarian murder of Robert Hamill has found police officers who were in a vehicle near the attack did not condone or collude with the attackers.

The report, published on Monday, external, highlighted multiple wrongful omissions in the subsequent murder investigation including a failure to properly search the home of a key suspect.

Robert Hamill was 25 when he died after he was beaten by loyalists in Portadown, County Armagh in 1997.

The inquiry concluded in 2009 and its report was completed in 2011 but the findings could not be published until three prosecutions in connection with the case concluded.

The inquiry concluded: “We find that Robert Hamill had been assaulted before the Land Rover officers got out of their vehicle.

“However, they were not aware of the assault and after they had got out of their vehicle, they attempted to restore order.

“They did not in any way condone or collude with attackers.”

Although the inquiry found that the four officers in the police vehicle could not have prevented the murder, the police investigation was flawed – both at the scene and in the days that followed.

“The inquiry found that serving RUC [Royal Ulster Constabulary] officers were guilty of wrongful omissions and that those omissions arose both at the scene and during the initial investigation,” it said.

The inquiry concluded that some of the mistakes in the investigation were negligent, while others were deliberate.

The 290-page report followed an inquiry which cost approximately £33m.

The killing of the young Catholic came during the peace process in Northern Ireland but was a reminder of the depth of the sectarian divisions which still existed.

Warmer weather could be on the way for parts of the UK

The Met Office has issued a verdict on the chances of the UK seeing a heatwave during September as temperatures begin to soar.

Greater Manchester is forecast to see temperatures rising up to 23C on Monday (September 14), according to Met Office weather maps, with areas across southern England also expected to reach 24C.

As temperatures appear to be on the rise across parts of the UK, some reports are suggesting hot weather could continue throughout September, as the Daily Star reports ‘warmer than average’ temperatures potentially stretching up to October 11.

Click here to get the biggest stories straight to your inbox in our Daily Newsletter

However the Met Office has warned the remainder of the month could bring a “fairly mixed picture across the UK”, adding that conditions could remain “changeable” for many.

Met Office Deputy Chief Forecaster Tony Wisson, said: “September is expected to continue to bring a fairly mixed picture across the UK, with a continuation of the changeable weather pattern we’ve seen recently. Weather systems moving in from the Atlantic are likely to continue to bring periods of rain and showers, combined with brighter and drier spells.

“The wettest and windiest conditions are expected to be focused across northern and western areas, while southern and eastern parts of the UK are more likely to experience longer dry periods and occasional warmer spells. Overall, temperatures are likely to be around average or slightly above average for the time of year.”

He continued: “Looking further ahead, there are some tentative signs that higher pressure could become more influential later in the month, potentially bringing settled conditions more widely for a time, but confidence in this remains relatively low at this stage.

“The strongest signal is for the current changeable pattern to continue, with areas of low pressure bringing further spells of rain, particularly in the north and west, while the south and east are more likely to see drier weather at times.”

While Greater Manchester is expected to see temperatures surpassing 20C on Monday, forecasters have suggested that they could once again drop over the remainder of the week. The Met Office warned the North West may feel “fresher than recent days” on Tuesday (September 15), with maximum temperatures reaching 18C.

Issuing a forecast for Wednesday to Friday this week across the North West, the Met Office said: “Changeable over the next few days and feeling fresher. Sunshine and showers will spread across the region, and it will turn increasingly windy.”

For people with Parkinson’s disease and their families, there is rarely much good news.

The neurological condition slowly robs sufferers of their ability to move freely and live independently, causing worsening tremors and muscle stiffness – and, for some, problems with memory and thinking.

And despite 166,000 people in the UK now diagnosed, there is still no cure or approved drug capable of slowing its progression. But that, doctors cautiously suggest, may finally be about to change.

Experts speaking to The Mail on Sunday have revealed we are on the cusp of a revolution in Parkinson’s treatment, with a new generation of drugs designed not simply to manage symptoms but to tackle the disease itself.

It means that, for the first time, these disease-modifying drugs – which could slow the progression of Parkinson’s and potentially even halt it – are on the near horizon and may be available within three years.

Other drugs which can better control symptoms with fewer debilitating side effects could also be available on the NHS as early as next year.

The advances are thanks to cutting-edge science which has unpicked the ways in which Parkinson’s develops – and the cascade of damaging processes these trigger in the brain. Crucially, diagnosis is also set to get faster, with pinprick blood tests already shown to pick up tell-tale signs up to seven years before symptoms emerge. This could allow treatment before too much damage has been done to brain cells – and when new drugs may be most effective.

And the need could hardly be greater. Parkinson’s is the world’s fastest-growing neurological disorder, with cases in the UK rising 38 per cent in 15 years.

US singer Carly Simon, 83, revealed her Parkinson’s diagnosis earlier this year and said the condition can be ‘frightening’ 

Globally, the number affected could double to more than 12 million by 2040.

Professor David Dexter, head of research at Parkinson’s UK and professor of neuropharmacology at Imperial College London, says there is now a real prospect of everyone in the UK who has Parkinson’s getting access to treatments which will improve their lives. And more astonishingly still, he argues that some people who have early signs of the disease in their blood – but who are not yet experiencing symptoms – may never go on to develop full-blown Parkinson’s because intervening early could hold it off for good.

‘The stars are really aligning when it comes to treating and potentially stopping Parkinson’s in its tracks,’ Prof Dexter says.

‘There’s a lot of positivity in the field. The promising thing is that these developments are likely to benefit people who are living with Parkinson’s now – even those in the later stages of the disease. And in the not-too-distant future we could be identifying people with Parkinson’s years before they’d ordinarily be diagnosed, giving them one of the new medications and preventing them from developing symptoms of the disease at all. We’re now at a stage where it’s feasible to think that way. It’s very exciting.’

One of the UK’s leading experts on the disease is Professor Miratul Muqit, who heads the UK Dementia Research Unit’s dedicated Parkinson’s Research Centre at the University of Edinburgh.

He cautiously shares Prof Dexter’s excitement while acknowledging challenges remain. He says: ‘We know so much more about the mechanisms of how this disease develops, and while the development of drugs to target these mechanisms remains challenging, what’s exciting is we have this new framework of knowledge about how cells in Parkinson’s are deteriorating.’

The new drugs that could slow it down

While Parkinson’s disease does not generally shorten lifespan, it can have a huge impact on the lives of sufferers.

Largely a disease of ageing, it is thought to be triggered by the accumulation of a normal brain protein called alpha synuclein, which forms abnormal clusters known as Lewy bodies. Precisely what causes the protein to form clumps remains unclear.

But scientists now understand that they gradually spread throughout the brain and damage the mitochondria – the ‘battery packs’ which power cells.

In turn, that damage stops brain cells producing enough dopamine, a chemical which plays a crucial role in controlling movement.

As levels fall, messages from the brain that control the muscles are disrupted, leading to the tremors, stiffness and slowed movement characteristic of Parkinson’s. Other symptoms include problems sleeping, depression, memory loss and balance issues.

Actor Michael J. Fox, who suffers from the condition, at a Parkinson’s fundraiser… the disease can often leave people needing a wheelchair and relying on physiotherapy to ease symptoms

These worsen over time – although each individual’s experience will be different – and can leave people needing a wheelchair, with speech and swallowing difficulties, incontinence and suffering hallucinations. About 80 per cent will eventually develop Parkinson’s-related dementia.

Treatment involves managing symptoms with physiotherapy, drugs such as levodopa which turn into dopamine in the brain, and dopamine agonists which mimic the effects of the chemical. Drugs known as MAO-B inhibitors also work to help increase dopamine in the brain.

These can be very effective in easing symptoms, but they do not stop the disease from progressing and some patients go on to require deep brain stimulation, a surgical procedure which places electrodes in the brain.

But now six drugs which could slow disease progression are in phase III trials – the crucial final stage of testing, in which treatments are typically given to hundreds or thousands of patients to confirm they work and are safe before regulators decide whether to approve them.

The most exciting is prasinezumab, an antibody treatment which binds to toxic clumps of alpha synuclein and stops it spreading from one cell to another. If it works, it would prove alpha synuclein’s role in Parkinson’s development, and that stopping it spreading slows the disease.

Its history is chequered because it failed to meet its main outcome – essentially, an improvement in a score which broadly measures Parkinson’s symptoms and function compared to a placebo – in an earlier trial. But when researchers looked specifically at an arm of that study which measured motor symptoms, the evidence suggested people taking the drug were deteriorating around 20 per cent more slowly.

A further analysis over the next two years confirmed those results, and found those also taking levodopa experienced less progression in their symptoms.

Six drugs which could slow disease progression are in the crucial final stage of testing. This includes prasinezumab, an antibody treatment, which stops it spreading from cell to cell

‘In the extended study, disease progression was 55 per cent slower in some patients receiving it after 2.5 years of treatment compared to placebo,’ says Prof Dexter. ‘It’s been shown to be very safe and doesn’t have the complicated side effects of some of the Alzheimer’s drugs which stopped NICE from approving them. We could get to a stage where you could give someone without symptoms this drug and it could be a game-changer – they may never develop the disease at all.’

The latest trial will report its results in 2029.

Several other drugs in the latest stages of trials are already licensed for other conditions which, if found to be effective, would make it even easier for patients to get access.

One is the cough medication ambroxol, a once-a-day pill which helps patients with respiratory disease to cough up mucus. It also boosts levels of an enzyme called GCase, which helps clear away waste products – such as alpha synuclein – from brain cells.

Trials involving a higher concentration of the drug are being run by researchers at University College London. ‘It would be quite easy for a manufacturer to gain a licence for Parkinson’s and gain regulatory approval quite quickly,’ says Prof Dexter. ‘It would be a lot cheaper for the NHS than a brand-new pharmaceutical.’

Existing medicines that may hold the key

One of the world’s biggest trials to evaluate new Parkinson’s treatments is also set to investigate three other drugs already licensed for use in other conditions.

The trial, EJS ACT-PD, will look at telmisartan, a blood pressure drug, terazosin, used to treat an enlarged prostate, and UDSA, a liver and gallstone drug.

Epidemiological studies have already found ‘very strong data’ that people taking telmisartan and terazosin for their original purpose have a lower rate of Parkinson’s disease, Prof Muqit says.

Lead researcher Professor Miratul Muqit says there is robust evidence that people taking telmisartan and terazosin have a lower rate of Parkinson’s disease

Advertisement

The trial is groundbreaking because it will allow many drugs to be tested together. And if one shows no effect after 18 months, it can be replaced with another.

‘It’s exciting, and we have to be optimistic, but we don’t yet really know how effective they are in Parkinson’s,’ says Prof Muqit. ‘It’s still uncertain.’

The final drug in late-stage trials is buntanetap, which reduces the production of toxic brain proteins, including alpha synuclein.

Even if these drugs all fail there are promising candidates further back in the development pipeline. They include one targeting the LRRK2 gene mutation, which is linked with Parkinson’s disease and may account for about 3 per cent of cases in the UK.

And there remains interest in the ability of GLP-1 drugs, used for type 2 diabetes and weight loss, to slow Parkinson’s by reducing brain inflammation.

Blood test that can spot it years early

Alongside improvements in treatment, the ability to pick up cases of Parkinson’s much earlier would make a huge difference to patient outcomes.

At present there is no definitive blood test or scan that can diagnose Parkinson’s.

Instead, doctors largely rely on symptoms and a clinical examination by a specialist, looking for signs such as tremor, stiffness and slowed movement.

Around 21,000 people in the UK are currently waiting for a diagnosis. Some have been waiting for years – and without one they cannot begin therapies that could help control their symptoms.

A blood test currently in development has identified a pattern of proteins in the blood that can predict whether someone will go on to develop Parkinson’s – years before symptoms emerge

A blood test in development by UCL researchers has already identified a pattern of proteins in the blood that can predict, up to seven years before symptoms emerge, whether someone will go on to develop Parkinson’s.

Tests are now under way to see whether the same protein signature can be detected using a simple dried blood spot – potentially requiring only a finger-prick sample – which could then be analysed in a hospital pathology lab using existing equipment.

The results so far are looking ‘quite promising’, Prof Dexter says.

He adds: ‘Currently they’re hoping this will improve the diagnostic journey and reduce waiting times. But if we can use the test in large studies, we could end up with something that identifies people early and allows them to take a disease-modifying drug before they develop symptoms.’

Better treatments and fewer side effects

The good news in the shorter term is that treatments to manage symptoms are improving.

Once-a-day pill tavapadon is being assessed by US regulator the Food and Drug Administration and may have fewer side effects than those currently available. It could be available in the UK next year, Prof Dexter says.

Tavapadon stimulates only two out of five dopamine receptors in the brain – unlike other similar drugs – and may reduce serious side effects which can cause compulsive behaviour such as excessive spending or over-eating.

Patients on trials reported significantly longer periods when their symptoms were under control.

Adaptive DBS, brain stimulators which control tremors automatically, are already being rolled out on the NHS and lead to much better symptom control.

And ondansetron – already used to manage sickness in people undergoing chemotherapy – is being tested to see if it can reduce the distressing hallucinations which affect up to 75 per cent of people with Parkinson’s.

‘When I speak to patient groups today, they get really excited because they can see things on the horizon which will benefit them,’ Prof Dexter says. ‘Finally, we have reached a point where real success could be very close.’

‘These are exciting times for Parkinson’s developments’ 

Anna Edwards, who was diagnosed ‘out of the blue’ with Parkinson’s nearly four years ago at the age of just 51, is optimistic about the progress being made to combat the disease. 

The professional gardener, pictured right, from Twickenham, south-west London, was diagnosed with the progressive neurological condition by a private doctor after she noticed a tremor and reduced motor control in her left hand. 

Advertisement

But the mother of two, who described the diagnosis as ‘a shock’, remains positive thanks to the wave of new drugs that have potential to slow the disease’s progress. 

Anna says: ‘There are a lot of trials coming to a point that is really quite exciting. I’ve been told 2026 is an exciting year for Parkinson’s developments, and that has been such a long time coming. I also have some agency in that, by staying active and exercising I can help slow things down.’ 

Anna’s tremor is well controlled with a levodopa-containing drug, and she is also now enrolled in a major trial, EJS ACT-PD, which is testing three drugs already in use for other conditions to see if they can slow the disease. 

‘Things seem to be going in the right direction,’ she says, ‘and while I’m not optimistic to the point of delusion, I know that, further down the line, some things might make a difference for me and for others.’

Advertisement

<!- – ad: https://mads.dailymail.co.uk/v8/de/health/none/article/other/mpu_factbox.html?id=mpu_factbox_1 – ->

• To get involved in Parkinson’s research, visit parkinsons.org.uk

A liver condition that many people have never heard of may affect around one in six women of childbearing age worldwide. A 2025 global analysis estimated that 15.8% of women aged 15 to 49 were living with metabolic dysfunction-associated steatotic liver disease (MASLD) in 2021.

Imagine Lisa, 31, arriving for her first pregnancy appointment. Five years earlier, routine blood tests had shown mildly raised liver enzymes, markers that can indicate liver damage. Further tests found excess fat in her liver. Because she also has obesity and type 2 diabetes, and other possible causes have been ruled out, her findings fit the diagnostic criteria for MASLD.

MASLD is the new name for what was previously called non-alcoholic fatty liver disease, or NAFLD. It describes excess fat in the liver alongside at least one metabolic risk factor, such as type 2 diabetes, high blood pressure, obesity or abnormal levels of fats in the blood.

Now that Lisa is pregnant, she has a simple question: what does this diagnosis mean for her and her baby?

The evidence is still developing. Pregnancy-specific research and guidance on MASLD remain much less extensive than the evidence available for the condition in the wider adult population.

The issue is becoming increasingly relevant. Between 2010 and 2021, the estimated global prevalence of MASLD among women aged 15 to 49 increased by almost 14%, with prevalence rising with age within this group.

The timing is notable. In May 2026, the World Health Assembly adopted a resolution recognising steatotic liver disease, the wider group of liver conditions that includes MASLD, as a growing global health challenge. It calls for better prevention, diagnosis and integration of liver disease into strategies addressing long-term conditions such as diabetes and cardiovascular disease.

Pregnancy itself causes substantial changes in how the body handles glucose and fats, including a gradual reduction in sensitivity to insulin, the hormone that helps move glucose from the blood into cells.

Evidence suggests that women with MASLD have higher rates of several pregnancy complications. An in-depth review of 22 studies involving 13,641 women with NAFLD found higher odds of gestational diabetes, high blood pressure during pregnancy, pre-eclampsia and preterm birth, meaning birth before 37 weeks. Most of these studies used the older NAFLD terminology.

Interpreting these findings is complicated because MASLD often occurs alongside obesity and other metabolic conditions that can themselves influence pregnancy outcomes. Earlier studies were also often small or unable to examine the severity of liver disease separately.

Using nationwide Swedish healthcare data, we and our colleagues studied 240 births to 162 women with biopsy-confirmed MASLD and compared them with 1,140 matched births to women without known MASLD.

One finding stood out. Preterm birth occurred in 16.7% of pregnancies among women with MASLD, compared with 4.7% in the comparison group. After accounting for other measured factors, the odds indicated a 3.4 higher risk of preterm birth.

The association remained when women with MASLD were compared with women who were overweight or had obesity but no known MASLD, and when researchers compared pregnancies within families to reduce the influence of shared genetic and environmental factors. This strengthens the evidence that MASLD may play a role, but the study was observational and therefore cannot prove that MASLD caused the premature births.

Having more advanced MASLD, including fibrosis, which means scarring of the liver, did not appear to further increase the risk of adverse pregnancy outcomes in the Swedish study. However, the numbers of women with more severe disease were small and the statistical uncertainty was substantial.

Women with MASLD also had higher odds of caesarean delivery. But that difference was no longer clear when they were compared with women who were overweight or had obesity without known MASLD, suggesting that body weight or related factors could account for much of the association.

What about the children?

The evidence is more limited. In another Swedish nationwide study, 239 children born to mothers with biopsy-confirmed MASLD had a higher rate of serious infections requiring hospital care than 1,131 comparison children. Across follow-up, their adjusted rate was about 1.8 times higher, with the strongest association during the first year of life, when it was about three times higher. Again, this was an observational finding and does not establish that maternal MASLD caused the infections.

There is some reassuring evidence too. The same Swedish cohort has so far shown no clear evidence of increased cancer or death through early adulthood. Another study found no statistically clear increase in autoimmune diseases, conditions in which the immune system mistakenly attacks the body’s own tissues.

These apparently reassuring findings also require caution. The studies contained only 239 children exposed to maternal MASLD and relatively few cases of cancer, death or autoimmune disease, so larger studies with longer follow-up are needed.

For women like Lisa, these uncertainties affect real conversations about pregnancy, monitoring and risk. As MASLD becomes increasingly common among women of childbearing age, doctors are likely to encounter it more often in pregnancy. Better evidence is needed to tell women what the diagnosis means for them and for their children.

Oasis are expected to announce a new run of shows for 2027 today at 4pm… and fans will be hoping that the ticket sale is nothing like the debacle of 2025.

The Manchester rock band found their long-awaited reunion tour the subject of unwanted attention after fans were hit with inflated ticket prices for their UK and Ireland shows.

When tickets for Oasis Live ‘25 were released, many fans were shocked at having to pay more than double face value, as some standard standing tickets were sold for £355 instead of the expected £148.

Some fans forked out thousands of pounds to see brothers Noel and Liam Gallagher onstage together for the first time since 2009.

Ticketing company Ticketmaster was accused of using dynamic pricing, an algorithmic strategy where prices surge in response to higher demand – while low demand can also lead to lower prices.

While the UK’s competition watchdog, the Competition and Markets Authority, did not find evidence that Ticketmaster used dynamic pricing, it concluded the company did not inform fans that standing tickets would be sold at two different prices, and that prices would go up as soon as the cheaper tickets sold out.

Following an investigation, Ticketmaster agreed in September last year that it would provide fans with considerably more information before and during their purchase of concert tickets.

Elsewhere, other fans were devastated after the company cancelled their tickets, having reportedly mistook them for bots.

Enjoy unlimited access to 100 million ad-free songs and podcasts with Amazon Music

Advertisement

Sign up now for a 30-day free trial. Terms apply.

Try for free

ADVERTISEMENT. If you sign up to this service we will earn commission. This revenue helps to fund journalism across The Independent.

Fans spoke of having their “dreams crushed” after receiving emails from the ticket-selling website informing them that their tickets to the rock band’s reunion shows were void.

Should the band confirm a new tour will take place next year, there is a strong chance that their team and Ticketmaster will have taken steps to avoid repeating the 2024 controversy.

Pop star Harry Styles recently added the final 25 dates to his Together, Together world tour, for which he is introducing “unpredictable fun” tickets where a limited number of £20 (or $20 / 20 euros) tickets will be made available.

This announcement landed after criticism from some of his fans over the ticket prices for the earlier dates, which in the UK ranged between £44.10 to £466.24 for seated tickets at Wembley, and standing prices between £144.65 to £279.45. VIP packages range from £468.85 to £725.45.

There is an ongoing debate surrounding what constitutes fair prices for fans in the current economy, amid a worrying trend in which a number of major artists have cancelled their tours – reportedly due to low ticket sales.

Oasis will certainly not face this issue – their 2025 tour was one of the most in-demand in recent memory, with tickets selling out within minutes of going on sale and generating millions in revenue.

Oasis Live ‘25 was estimated by Forbes to have generated over $400m (£293m) in revenue, with Noel and Liam each pocketing between $50m-$100m. As a result, the pair cracked the Sunday Times Rich List this year with a combined net worth of $375m.

Follow the latest on Oasis’s announcement today here.

Sophie Potter, 19, from Merseyside was last seen on Saturday, September 12, after attending the Reminisce Festival at Sherdley Park in St Helens

The relatives of a teenager who vanished without her mobile phone following a music festival are making an urgent appeal to locate her. Sophie Potter, 19, from Merseyside was last spotted on Saturday, September 12.

She had been at the Reminisce Festival at Sherdley Park in St Helens, reports the Mirror. Sophie had attended the event with her parents but became separated at approximately 10pm, shortly before DJ Lee Butler was due to take to the stage.

She was last spotted outside the festival grounds at roughly 11.30pm. Sophie was last spotted dressed in a baby pink top and shorts along with her dad’s black tracksuit top.

Her parents grew concerned when she failed to come home. Her auntie, Samantha Potter, revealed the teenager’s mobile has been handed back to her family.

She explained: “Sophie got separated from her mum at about 10pm. It was so crowded – one minute she was there, next minute she was gone. Her mum left early – she thought, if she’s going out, I’ll catch her that way.

“Sophie is dead chatty. She was dead excited. She was going with her mum and dad. She’d been talking to a few people in there. We were thinking (she’d turn up at home) – she’s met up with some people or seen someone from school.

“We’d been worried all day yesterday. We rang hospitals in case she’d been there. This is very out of character. She lost her phone on the night as well – someone found it and we’ve got it back – but she hasn’t called her number either. We’re really worried as the time is going on.”

Samantha revealed the family received a fresh lead from a neighbour following yesterday’s online appeal, though Sophie’s whereabouts remain unknown.

She explained: “We’ve posted it and since then we had the neighbour contact us. We’ve just spoken to them and they saw her at 11.30pm outside. We’re hoping someone else will give us something to go on.

“We’ve contacted everyone we can think of. She’s got a brother and niece the same age. They’ve been everywhere looking for her. We’re up the wall at the moment.”

The missing person appeal has been circulated extensively online, with Lee Butler among those sharing it. Samantha urged anyone with information about Sophie’s location to get in touch with police immediately.

Merseyside Police described Sophie as approximately 5ft 3in tall, of slim build with dark hair. She has a henna tattoo on her left hand, a birthmark on her right shoulder and a belly button piercing.

Officers confirmed that when Sophie disappeared, she was dressed in a pink belly top, pink shorts and a black Montirex jacket.

Anyone with information about Sophie’s whereabouts should contact Merseyside Police on 101 or send a direct message via social media @MerPolCC. Sightings can also be reported through the online form at: https://www.merseyside.police.uk/ro/report/mp/v2/add-something-erated-missing/.

Ensure our latest stories always appear at the top of your Google Search by making us a Preferred Source. Click here to activate or add us as your Preferred Source in your Google search settings.